Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFNα-2a in Postmastectomy Breast Reconstruction
NCT04522557Phase 1Completed
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Aug 2020
- Primary completion
- Jul 2021
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of interferon alfa-2a in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Dose-limiting toxicity at 7 days. Started Aug 2020; status: completed.
02
Drugs
interferon alfa-2a
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04522557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04522557.